Bioorganic Research and Services : September Newsletter
September 09, 2014 at 07:31 am
Share
Biological drugs: a fact
Nowadays, 50% of drugs in development have a biological origin, according to Farmaindustria. They are a new generation of substances that improve the features of traditional medicines (chemically-based ones) and are intended -most of them- to fight diseases in a more specific way. The advances in genetic knowledge and the application of new technologies to health make possible the scientific research to take important steps in this way. In fact, these compounds are already gaining ground to the traditional medicines in the worldwide market[...] Read more
One of the current challenges of BBD BioPhenix (acquired by Bionaturis) is gaining position in other markets different from pharmaceutical or veterinarian ones. The versatility of its services and the high capability of its facilities to the tailor made requirements of its customers make BBD an essential partner in drug discovery research for other sectors such as agrochemical, petrochemical, cosmetics and nutraceutical. "We are already working in interesting projects outside the pharmaceutical arena thanks to the suitable features of the zebra fish model for active ingredients screening and our intention is going on this track", R&D manager Arantza Muriana, states. [...] Read more
Emilio Moraleda: keys for
a good leader
Emilio Moraleda, board member of Bionaturis, has described in a recent article one of the keys for a good leader: the capacity of constant self-demanding. For the former president of Farmaindustria and Manager Director of the pharmaceutical giant Pfizer in Europe, a leader should aim always to improve even more when the results are excellent. The conformity and the self-indulgence are, then, two features that a good leader must avoid under any circumstances to be always in the top [...] Read more
Biotechnology Assets SA, formerly known as ADL Bionatur Solutions SA, is a Spain-based biotech company. The Firmâs main activities are: Research, development and production of biotechnological solutions aimed at improving the health and welfare of people and animals; Development, acquisition, transfer and exploitation of industrial and intellectual property rights; Distribution, marketing, export and import of the previously mentioned products. The Company, through its subsidiaries, is also present in Luxembourg, Hong Kong and USA.